The DNPH1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung epithelial carcinoma cell line. This product provides a heterogeneous pool of cells carrying targeted disruptions in the DNPH1 gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves natural genetic variability while ensuring robust knockout across the population, suitable for functional assays where gene disruption is confirmed at the population level.
The parental A-549 cell line, established from a lung adenocarcinoma of a Caucasian male, exhibits adherent epithelial morphology and is a widely used model for alveolar adenocarcinoma. These cells are extensively employed in respiratory research, cancer biology, and drug metabolism studies due to their relevance to non-small cell lung cancer. A-549 cells harbor wild-type p53 and express lung epithelial markers, making them a versatile platform for investigating tumorigenic mechanisms and therapeutic responses.
DNPH1 encodes a deoxynucleoside monophosphate hydrolase that catalyzes the hydrolysis of deoxynucleoside monophosphates (dNMPs) to deoxynucleosides and inorganic phosphate. This reaction critically regulates dNTP precursor pools, balancing nucleotide salvage and degradation pathways. DNPH1 activity is transcriptionally controlled by cell cycle regulators, notably the transcription factor E2F1, and its function directly impacts DNA synthesis and replication fidelity. By modulating dNTP levels, DNPH1 prevents aberrant nucleotide incorporation and genotoxic stress. The enzyme interacts with substrate dNMPs and nucleotide kinases, positioning it at a key node in nucleotide metabolism and the DNA replication checkpoint. Disruption of DNPH1 thus perturbs dNTP homeostasis and impairs cell proliferation under replication stress conditions.
In the context of A-549 lung adenocarcinoma cells, DNPH1 knockout is particularly relevant for studying the interplay between nucleotide metabolism and tumor growth. Lung cancer cells often exhibit elevated dNTP pools and enhanced DNA replication rates, processes that are dependent on enzymes like DNPH1. The polyclonal knockout population enables the investigation of how DNPH1 loss affects cancer cell viability, genomic stability, and drug sensitivity, especially to agents that target nucleotide synthesis or DNA damage response pathways. This model aids in clarifying the role of dNMP hydrolysis in maintaining balanced dNTP supply during uncontrolled proliferation.
Researchers can employ these cells for diverse functional assays, including western blotting and RT-qPCR to confirm DNPH1 knockout, nucleotide pool quantification by mass spectrometry, cell proliferation and clonogenic survival assays. The polyclonal knockout cells are also suitable for high-throughput screening of compounds that modulate nucleotide metabolism or DNA replication checkpoint function. Importantly, the product serves as an ideal matched control for CRISPR experiments, enabling side-by-side comparison with parental A-549 cells to dissect DNPH1-specific phenotypes. For further information, technical support, or to discuss custom modifications, please contact Ascent Research.
